Search Within

Gunjan Lalitchandra Shah

Formats
  1. Meeting Abstract (272)
  2. Journal Article (124)
  3. Research Letter (13)
  4. Review (6)
  5. Correspondence (2)
  6. Guidelines (1)
Groups
  1. Bone Marrow Transplant (418)
  2. Center for Hematologic Malignancies (418)
  3. Department of Medicine (418)
  4. Hematologic Malignancies, Division of (418)
  5. Survivorship Research (418)
  6. CTCR Scholars (321)

More Groups

People
  1. Sergio Giralt (297)
  2. Michael Scordo (277)
  3. Miguel-Angel Perales (192)
  4. Sean Devlin (177)
  5. Parastoo Dahi (155)
  6. Heather Landau (154)

More People

Years
  1. 2025 (12)
  2. 2024 (54)
  3. 2023 (85)
  4. 2022 (55)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Blood (137)
  2. Biology of Blood and Marrow Transplantation (73)
  3. Clinical Lymphoma, Myeloma and Leukemia (39)
  4. Transplantation and Cellular Therapy (23)
  5. Blood Advances (20)
  6. Bone Marrow Transplantation (19)

More Publications

Publishers
  1. American Society of Hematology (157)
  2. Elsevier Inc. (142)
  3. Nature Publishing Group (31)
  4. American Society of Clinical Oncology (14)
  5. Taylor & Francis Group (9)
  6. Wiley Blackwell (7)

More Publishers

Results (418)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing autologous hematopoietic stem cell transplant (AHCT)
    Meeting Abstract

    Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S. J.; Hoover, E.; Chung, D. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Pharmacokinetics and toxicities after Evomela® (propylene glycol free melphalan) with autologous hematopoietic stem cell transplant (AHCT) for multiple myeloma and AL amyloidosis
    Meeting Abstract

    Shah, G. L.; Landau, H.; Sarubbi, C.; Schofield, R.; Lin, A.; Bhatt, V.; Harnicar, S. J.; Devlin, S. M.; Chung, D. J.; Dahi, P. B.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Long-term follow-up of adult double unit cord blood (CB) transplantation (dCBT) recipients reveals high rates of progression-free survival after a novel cy/flu/thio/TBI 400 intermediate intensity conditioning regimen
    Meeting Abstract

    Politikos, I.; Devlin, S. M.; Jacob, A.; Maloy, M.; Mazis, C.; Naputo, K.; Scaradavou, A.; O'Reilly, R.; Avecilla, S.; Castro-Malaspina, H. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • More intensive fludarabine/busulfan (Flu/Bu) conditioning regimens result in similar outcomes without adding serious toxicity when compared to fludarabine/melphalan (Flu/Mel) in patients undergoing allogeneic hematopoietic cell transplant (Allo-HCT)
    Meeting Abstract

    Pappacena, J.; Bhatt, V.; Shah, G. L.; Hilden, P.; Maloy, M.; Buie, L. W.; Giralt, S. A.; Scordo, M.
    Blood (2017)

    Fulltext@MSK | Save
  • Costs and in-hospital mortality rates in autologous stem cell transplant for multiple myeloma: An analysis of the Nationwide Inpatient Sample (NIS) Database
    Meeting Abstract

    Liu, Y.; Han, H.; Wei, X.; Wang, Q.; He, J.; Shah, G. L.; Giralt, S. A.; Landgren, O.; Lesokhin, A.
    Blood (2017)

    Fulltext@MSK | Save
  • MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A cost-benefit analysis of bortezomib, lenalidomide, and bortezomib/lenalidomide combination therapy for newly diagnosed multiple myeloma
    Meeting Abstract

    Fiala, M. A.; Wildes, T. M.; Shah, G. L.; Ghobadi, A.; Schroeder, M. A.; Stockerl-Goldstein, K. E.; Vij, R.
    Blood (2017)

    Fulltext@MSK | Save
  • Quantitative analysis of T1-weighted MRI images as a surrogate for fat content does not correlate with response or survival
    Meeting Abstract

    Amer, A.; Gunjan, S.; Benjamin, D.; Sean, D.; Molly, M.; Yousef, M.; David, C.; Guenther, K.; Nikoletta, L.; Heather, L.; more...
    Bone Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Vaccines are safe and effective after T-cell depleted CD34-selected allogeneic hematopoietic stem cell transplantation (Allo HCT)
    Meeting Abstract

    Malard, F.; Shah, G. L.; Seier, K.; Cho, C.; Devlin, S. M.; Maloy, M.; Borrill, T.; Palazzo, M.; van den Brink, M.; Perales, M. A.
    Bone Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • The impact of toxicities on first-year outcomes after ex vivo CD34(+)-selected allogeneic hematopoietic cell transplantation in adults with hematologic malignancies
    Journal Article

    Kosuri, S.; Herrera, D. A.; Scordo, M.; Shah, G. L.; Cho, C.; Devlin, S. M.; Maloy, M. A.; Nieves, J.; Borrill, T.; Carlow, D. C.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save